Previous 10 | Next 10 |
2023-10-20 15:00:13 ET More on the markets S&P 500 Will Likely Underperform And 5% Money Markets Are NOT The Answer Equities Climbing A Wall Of Worry (Technical Analysis) SPY: Short-Term Bounce Testing The Downtrends (Technical Analysis) Here is why you s...
According to American Cancer Society Facts and Figures, breast cancer is the most common cancer in the United States with 300,590 expected new cases in 2023 43,700 women and men are expected to die of breast cancer in the U.S. in 2023, making breast cancer the 2nd leading cause of can...
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer ca...
Dr. Adam M. Brufsky of University of Pittsburgh School of Medicine and Dr. Saranya Chumsri of Mayo Clinic will discuss the current treatment landscape for patients with advanced metastatic breast cancer and the latest clinical data of the Bria-IMT™ regimen BriaCell recently rep...
PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform canc...
The randomized pivotal Phase 3 study is expected to enroll a total of 354 patients in either Bria-IMT™ combination or physician’s choice therapy (1:1) Positive results of the pivotal Phase 3 study could result in full approval and marketing authorization for Bria...
2023-09-13 09:00:30 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 13, 2023 – USA News Group – Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food and Drug Administr...
2023-09-10 00:26:34 ET Summary BriaCell Therapeutics is developing a cell therapy vaccine for breast cancer using a research cell line that has been used for decades. The company's main therapeutic candidate, Bria-IMT, has shown preliminary safety and efficacy in clinical trials, ...
2023-09-08 15:09:33 ET More on Briacell Seeking Alpha’s Quant Rating on Briacell Therapeutics Historical earnings data for Briacell Therapeutics Financial information for Briacell Therapeutics For further details see: BriaCell falls after Phase 2 d...
Median overall survival of 13.5 months in BriaCell’s advanced metastatic breast cancer patients (vs. 6.7-9.8 months for similar patients reported in the literature) 21 out of 29 patients treated since 2022 are still alive suggesting a strong survival benefit for BriaCell's co...
News, Short Squeeze, Breakout and More Instantly...
BriaCell Therapeutics Corp. Company Name:
BCTX Stock Symbol:
NASDAQ Market:
PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer car...
Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MD Two poster presentations include Drs. Hurvitz (Fred Hu...
Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MD Two poster presentations include Drs. Hurvitz (Fred Hutchinson Cancer Center), Brufsky (UPMC), and Cristofanilli (Weill Cornell) as authors PHILADELPHIA and VANCOUVER, British Columb...